{"nctId":"NCT02992925","briefTitle":"Phase 3 Study of BK1310 in Healthy Infants","startDateStruct":{"date":"2016-11"},"conditions":["Immunization; Infection"],"count":370,"armGroups":[{"label":"Cohort 1: BK1310-High","type":"EXPERIMENTAL","interventionNames":["Biological: DPT-IPV-Hib-High（Combined Vaccine）"]},{"label":"Cohort 1: BK1310-Low","type":"EXPERIMENTAL","interventionNames":["Biological: DPT-IPV-Hib-Low（Combined Vaccine）"]},{"label":"Cohort 2: BK1310-High or -Low","type":"EXPERIMENTAL","interventionNames":["Biological: DPT-IPV-Hib-High（Combined Vaccine）","Biological: DPT-IPV-Hib-Low（Combined Vaccine）"]},{"label":"Cohort 2: ActHIB® and Tetrabik","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hib vaccine","Biological: DPT-IPV"]}],"interventions":[{"name":"DPT-IPV-Hib-High（Combined Vaccine）","otherNames":["BK1310-High"]},{"name":"DPT-IPV-Hib-Low（Combined Vaccine）","otherNames":["BK1310-Low"]},{"name":"Hib vaccine","otherNames":["ActHIB®"]},{"name":"DPT-IPV","otherNames":["Tetrabik"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants aged ≥2 and \\<43 months at the first vaccination of the study drug (recommended: ≥2 and \\<7 months). Those who are applicable of the following conditions must be carefully observed before the enrollment: infants with known underlying disease such as cardiovascular disease, renal disease, hepatic disease, blood dyscrasia, respiratory disease or developmental disorder. Infants who developed fever within 2 days after any previous vaccination. Infants with history of convulsions.\n* Written informed consent is obtained from a legal guardian (parent)\n\nExclusion Criteria:\n\n* With past diagnosis of immunodeficiency or currently under immunosuppressive treatment\n* Have close relatives (the third degree of kinship) diagnosed with congenital immunodeficiency\n* Possibility of anaphylaxis due to food or pharmaceuticals\n* With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis\n* With experience of Hib, diphteria, pertussis, tetanus or polio vaccination.\n* Administered a live vaccine within 27 days before the first vaccination of the study drug, or inactivated vaccine or toxoid within 6 days before vaccination\n* Administered transfusion, immunosuppressant (excluding drugs for external use), or immunoglobulin formulation\n* Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs for external use)\n* Participated in other studies within 12 weeks before obtaining consent\n* With the gestational age \\<37 weeks or weighed less than 2500 grams at birth.\n* Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"43 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP","description":"Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \\>=0.1 IU/mL, Anti-PT antibody concentrations: \\>=10.0 EU/mL, Anti-FHA antibody concentrations: \\>=10.0 EU/mL, Anti-tetanus antibody concentrations: \\>=0.01 IU/mL, Anti-poliovirus serotype 1, 2 and 3, antibody titers (fold) \\>=8","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"99.4","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer of Anti-PRP Antibody","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.613","spread":null},{"groupId":"OG001","value":"23.097","spread":null},{"groupId":"OG002","value":"17.832","spread":null},{"groupId":"OG003","value":"6.245","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer of Anti-PRP Antibody","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.937","spread":null},{"groupId":"OG001","value":"54.333","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Diphtheria Toxin","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1640","spread":null},{"groupId":"OG001","value":"0.8058","spread":null},{"groupId":"OG002","value":"0.8767","spread":null},{"groupId":"OG003","value":"0.7010","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis （PT）","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208.80","spread":null},{"groupId":"OG001","value":"180.78","spread":null},{"groupId":"OG002","value":"175.35","spread":null},{"groupId":"OG003","value":"184.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis （FHA）","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.41","spread":null},{"groupId":"OG001","value":"49.99","spread":null},{"groupId":"OG002","value":"57.59","spread":null},{"groupId":"OG003","value":"83.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Tetanus Toxin","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5320","spread":null},{"groupId":"OG001","value":"0.4032","spread":null},{"groupId":"OG002","value":"0.4950","spread":null},{"groupId":"OG003","value":"0.2807","spread":null}]}]}]},{"type":"SECONDARY","title":"Fold Change in Geometric Mean Antibody Titer Against Polio Virus","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"933.60","spread":null},{"groupId":"OG001","value":"588.13","spread":null},{"groupId":"OG002","value":"742.01","spread":null},{"groupId":"OG003","value":"885.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1824.56","spread":null},{"groupId":"OG001","value":"1955.52","spread":null},{"groupId":"OG002","value":"2137.58","spread":null},{"groupId":"OG003","value":"1978.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"851.19","spread":null},{"groupId":"OG001","value":"1320.32","spread":null},{"groupId":"OG002","value":"1430.55","spread":null},{"groupId":"OG003","value":"1551.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Prevalence Rate Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus","description":"Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \\>=0.1 IU/mL, Anti-PT antibody concentrations: \\>=10.0 EU/mL, Anti-FHA antibody concentrations: \\>=10.0 EU/mL, Anti-tetanus antibody concentrations: \\>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \\>=8","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Diphtheria Toxin","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9090","spread":null},{"groupId":"OG001","value":"10.2457","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis （PT）","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.34","spread":null},{"groupId":"OG001","value":"223.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis （FHA）","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.20","spread":null},{"groupId":"OG001","value":"85.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Tetanus Toxin","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1670","spread":null},{"groupId":"OG001","value":"1.0640","spread":null}]}]}]},{"type":"SECONDARY","title":"Fold Change in Geometric Mean Antibody Titer Against Polio Virus","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4597.60","spread":null},{"groupId":"OG001","value":"1910.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7822.06","spread":null},{"groupId":"OG001","value":"6501.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4815.04","spread":null},{"groupId":"OG001","value":"4096.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Injection site erythema","Pyrexia","Injection site induration","Injection site swelling","Hypersomnia"]}}}